Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Divalent metal cations, including essential transition metals like copper (Cu) and zinc (Zn) and toxic heavy metals like lead (Pb), mercury (Hg), cadmium (Cd), and nickel (Ni), are inorganic entities with critical roles in human biology and pathology. Essential metals serve as indispensable cofactors for enzymes such as superoxide dismutase and cytochrome c oxidase, and are vital for the structural integrity of zinc-finger transcription factors [1][2]. However, excessive accumulation of essential metals or exposure to non-essential heavy metals leads to systemic toxicity by displacing necessary ions from protein binding sites, inhibiting enzyme function, and inducing oxidative stress through the generation of reactive oxygen species [3][4]. In clinical practice, these ions are the primary targets for chelating agents like penicillamine, EDTA, and succimer, which sequester the free ions into stable, water-soluble complexes to facilitate their renal clearance [5][6]. Therapeutic management of these targets is essential in treating conditions such as Wilson's disease, Menkes disease, and acute or chronic heavy metal poisoning, with efficacy monitored through blood and urinary metal levels [4][5]. Sources: [1] PubChem (NCBI). "Copper" and "Zinc". [2] UniProt. "Zinc-finger protein family". [3] ATSDR. "Toxicological Profiles for Lead, Mercury, and Cadmium". [4] StatPearls. "Heavy Metal Toxicity". [5] StatPearls. "Chelating Agents". [6] NIDDK. "Wilson's Disease".
Chelation therapy involves the administration of ligands that compete with endogenous biological ligands for metal binding, forming stable, water-soluble coordination complexes that are subsequently excreted from the body via the kidneys or bile [5][6].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Divalent metal cation (Copper, Zinc, Nickel, Cadmium, Lead, Mercury).